Compare · NVO vs WHWK
NVO vs WHWK
Side-by-side comparison of Novo Nordisk A/S (NVO) and Whitehawk Therapeutics Inc. (WHWK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and WHWK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 1065.0x WHWK ($209.2M).
- Over the past year, NVO is down 22.5% and WHWK is up 111.4% - WHWK leads by 133.9 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for WHWK).
- NVO has more recent analyst coverage (25 ratings vs 3 for WHWK).
- Company
- Novo Nordisk A/S
- Whitehawk Therapeutics Inc.
- Price
- $50.31-2.25%
- $3.89+0.39%
- Market cap
- $222.81B
- $209.2M
- 1M return
- +15.47%
- -6.94%
- 1Y return
- -22.53%
- +111.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 3
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest WHWK
- Leerink Partners initiated coverage on Whitehawk Therapeutics with a new price target
- Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
- B. Riley Securities initiated coverage on Whitehawk Therapeutics with a new price target
- SEC Form 4 filed by Director Zhao Baiteng
- SEC Form 4 filed by Director Reeve Emma
- SEC Form 4 filed by Director Maroun Richard E
- SEC Form 4 filed by Director Hirmand Mohammad
- SEC Form 4 filed by Director Desai Neil
- SEC Form 4 filed by Director Castelein Caley
- SEC Form 4 filed by Director Aghazadeh Behzad